Pictet Asset Management SA Grows Holdings in ShockWave Medical, Inc. (NASDAQ:SWAV)

Pictet Asset Management SA raised its position in ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) by 6.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,232 shares of the company’s stock after purchasing an additional 144 shares during the period. Pictet Asset Management SA’s holdings in ShockWave Medical were worth $427,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC lifted its holdings in ShockWave Medical by 219.7% in the 2nd quarter. CWM LLC now owns 195 shares of the company’s stock valued at $37,000 after purchasing an additional 134 shares in the last quarter. AdvisorShares Investments LLC purchased a new position in shares of ShockWave Medical during the 1st quarter worth about $40,000. PenderFund Capital Management Ltd. purchased a new position in shares of ShockWave Medical during the 1st quarter worth about $41,000. First Horizon Advisors Inc. lifted its holdings in shares of ShockWave Medical by 3,666.7% during the 2nd quarter. First Horizon Advisors Inc. now owns 226 shares of the company’s stock worth $43,000 after acquiring an additional 220 shares during the period. Finally, Signaturefd LLC lifted its holdings in shares of ShockWave Medical by 73.6% during the 1st quarter. Signaturefd LLC now owns 224 shares of the company’s stock worth $46,000 after acquiring an additional 95 shares during the period. 95.40% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ShockWave Medical

In other ShockWave Medical news, Director Maria Sainz sold 650 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $295.00, for a total value of $191,750.00. Following the completion of the sale, the director now owns 5,316 shares of the company’s stock, valued at $1,568,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other ShockWave Medical news, Director Maria Sainz sold 650 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $295.00, for a total value of $191,750.00. Following the completion of the sale, the director now owns 5,316 shares of the company’s stock, valued at $1,568,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $308.25, for a total transaction of $1,233,000.00. Following the completion of the sale, the insider now directly owns 73,563 shares of the company’s stock, valued at approximately $22,675,794.75. The disclosure for this sale can be found here. Insiders sold 58,450 shares of company stock valued at $15,199,064 over the last 90 days. 3.90% of the stock is owned by corporate insiders.

ShockWave Medical Stock Up 4.7 %

SWAV opened at $264.06 on Thursday. The firm has a 50 day moving average price of $270.82 and a 200 day moving average price of $235.08. The company has a market cap of $9.54 billion, a PE ratio of 113.33 and a beta of 1.03. ShockWave Medical, Inc. has a 1 year low of $113.36 and a 1 year high of $320.54. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.02 and a current ratio of 7.29.

Wall Street Analysts Forecast Growth

SWAV has been the topic of several recent analyst reports. Morgan Stanley increased their price objective on shares of ShockWave Medical from $255.00 to $290.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 11th. Bank of America increased their price objective on shares of ShockWave Medical from $260.00 to $310.00 in a report on Monday, November 7th. Canaccord Genuity Group increased their price objective on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Piper Sandler increased their price objective on shares of ShockWave Medical from $278.00 to $338.00 and gave the stock an “overweight” rating in a report on Monday, August 29th. Finally, Oppenheimer downgraded shares of ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 target price for the company. in a research report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $263.00.

ShockWave Medical Company Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Featured Articles

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.